WuXiPRA Names James Pusey President and General Manager
SHANGHAI and RALEIGH, N.C., July 16, 2013
SHANGHAI and RALEIGH, N.C., July 16, 2013 /PRNewswire/ -- WuXiPRA, a contract
research organization (CRO) that offers Phase I-IV clinical trial services in
China, Hong Kong, and Macau, today announced that James Pusey, M.D., has
joined WuXiPRA as president and general manager. Dr. Pusey has more than 25
years of experience in medicine, international clinical trial management, CRO
services, and global pharmaceutical sales, marketing, and clinical operations.
Prior to joining WuXiPRA, Dr. Pusey was founding CEO of Theorem Clinical
Research, where he served as president and chief executive officer, executive
chairman, and board director from 2009 through 2013. Previously, Dr. Pusey
served as senior vice president and general manager of global clinical
development at MDS Pharma Services. During his tenure at both of these global
CROs, he successfully reorganized and developed their Asian businesses for
Dr. Pusey has also served as president and chief executive officer of
Orthologic, Inc., a biotechnology company based in Phoenix, Arizona; as
executive vice president of the Pfizer/Serono joint venture on multiple
sclerosis; and in a variety of roles at AstraZeneca and SmithKline Beecham.
Before his business career, Dr. Pusey was a practicing physician at Royal Free
Hospital, King George Hospital, St. Bartholomew's Hospital, and the
Whittington Hospital, all based in London.
"We are pleased that Dr. Pusey has joined the company," said Colin Shannon,
president and CEO, PRA. "His global experience in the CRO market will be an
asset to WuXiPRA. With clinical trials continuing to expand in China, having
Dr. Pusey onboard will allow us to establish a stronghold in the region."
"Under James's leadership, we believe WuXiPRA will become the clinical CRO of
choice in China," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "WuXi
PharmaTech's local expertise and PRA's leading-edge global systems and
processes will enable customers to conduct the highest-quality clinical trials
in China quickly and successfully for Chinese and international regulatory
WuXiPRA Clinical Research (Shanghai) Co., Ltd. was formed in 2013 to provide
clinical services in China for all PRA and WuXi clients around the globe.
WuXiPRA has access to several thousand registered clinical trial sites in
China and is focused on providing high-quality regulatory and operational
services for those sites. WuxiPRA has offices in Beijing, Shanghai, Wuhan,
Hong Kong, and Guangzhou and access to significant resources at both WuXi and
PRA to provide customers with high-quality data and regulatory submissions.
About WuXi PharmaTech
As a research-driven and customer-focused company, WuXi PharmaTech (Cayman)
Inc. provides a broad and integrated portfolio of laboratory and manufacturing
services throughout the drug and medical device R&D process. WuXi PharmaTech's
services are designed to assist its global partners in shortening the cycle
and lowering the cost of drug and medical device R&D. WuXi AppTec is the name
for the operating subsidiaries of WuXi PharmaTech. For more information,
please visit: http://www.wuxiapptec.com .
PRA serves our clients across all phases of pharmaceutical and biotech drug
development by combining therapeutic and operational expertise with local
knowledge. Offering services in 80+ countries and serving sponsors for 30+
years, we have amassed a level of expertise that has enabled us to work on a
variety of compounds, ranging from niche treatments and therapies to
blockbuster drugs. But at PRA, we are looking to the future, not the past. Our
increasingly forward-thinking approach to transforming the clinical trial
landscape will continue to make a difference to healthcare patients around the
world. To learn more about PRA, please visit http://www.praintl.com .
Cautionary Note Regarding Forward-Looking Statements for WuXi PharmaTech
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements are not historical facts, but instead are predictions about future
events. Examples of forward-looking statements in this press release include
statements about growth in clinical trials in China and the ability of WuXiPRA
to provide highest-quality clinical trial services for the Chinese market.
Although WuXi PharmaTech believes that the predictions are reasonable, future
events are inherently uncertain, and the forward-looking statements may turn
out to be incorrect. The forward-looking statements are subject to risks
relating to, among other things, the possibility that WuXiPRA may experience
operational difficulties and may fail to capitalize on the opportunities
presented. Additional information about these and other relevant risks can be
found in WuXi PharmaTech's Annual Report on Form 20-F for the year ended
December 31, 2012. The forward-looking statements in this press release speak
only as of the date on which they are made, and WuXi PharmaTech assumes no
obligation to update any forward-looking statements except as required by law.
Ronald Aldridge, Director of Investor Relations, WuXi PharmaTech
+1 (201) 585-2048
Aaron Shi, Assistant Director, Corporate Communications, WuXi PharmaTech
Laura Lawton, Public Relations, PRA
+1 (919) 786-8368
SOURCE WuXi PharmaTech (Cayman) Inc.
Press spacebar to pause and continue. Press esc to stop.